Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors
Harvard University · Massachusetts General Hospital · +3 more institutions
Abstract
Elevated interstitial fluid pressure, a hallmark of solid tumors, can compromise the delivery of therapeutics to tumors. Here we show that blocking vascular endothelial growth factor (VEGF) signaling by DC101 (a VEGF-receptor-2 antibody) decreases interstitial fluid pressure, not by restoring lymphatic function, but by producing a morphologically and functionally "normalized" vascular network. We demonstrate that the normalization process prunes immature vessels and improves the integrity and function of the remaining vasculature by enhancing the perivascular cell and basement membrane coverage. We also show that DC101 induces a hydrostatic pressure gradient across the vascular wall, which leads to a deeper…
Citation impact
- FWCI
- 28.13
- Percentile
- 100%
- References
- 32
Authors
6- RTRicky T. TongCorresponding
Harvard University, Massachusetts General Hospital, Harvard–MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology
- YBYves Boucher
Harvard University, Massachusetts General Hospital
- SVSergey V. Kozin
Harvard University, Massachusetts General Hospital
- FWFrank Winkler
Harvard University, Massachusetts General Hospital
- DJDaniel J. Hicklin
SciClone Pharmaceuticals (United States)
Topics & keywords
- Vascular endothelial growth factor
- Vascular permeability
- Neuropilin 1
- Blockade
- Kinase insert domain receptor
- Hydrostatic pressure
- Receptor
- Lymphatic system
- Good health and well-being